Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Summary

The purpose of this study is to evaluate the effect of SCH 900271 compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 8 weeks of treatment in participants with primary hypercholesterolemia (familial and nonfamilial) or mixed hyperlipidemia. The study will also evaluate the effect of SCH 900271 on non-high density lipoprotein cholesterol (non-HDL-C) and various other lipids and lipoproteins. The safety of SCH 900271 in this participant population will also be evaluated.

Timeline

Start

2009-06-29

Primary completion

2010-02-22

Completion

2010-02-22

Outcome

Met primary endpoint

registry SCH 900271 5 mg vs Placebo; p <0.01; Difference in percent -5.7 (95% CI -9.4 to -2.0); ANOVA NCT00941603 ↗

Drugs

Indications